1.6 mg — studied in a trial
1.6 mg twice a week, for 26 or 52 weeks, in a 98-patient randomized trial in chronic hepatitis B, under the skin.
1.6 mg once daily for the first week, then twice a week to week 12, in a 120-patient randomized trial in hepatitis-B-related acute-on-chronic liver failure, under the skin.
1.6 mg every 12 hours for up to seven days, under the skin. The regimen of the 1,106-participant phase 3 trial that found no mortality benefit.
| Water added | Concentration | Draw |
|---|---|---|
| 1 mL | 5.00 mg/mL | 32.0 units |
| 2 mL | 2.50 mg/mL | 64.0 units |
Human trialChien RN, et al. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J Viral Hepat 2006;13(12):845-50 · retrieved 2026-08-12
Human trialChen JF, et al. Safety and efficacy of Thymosin alpha1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int 2022;16(4):775-88 · retrieved 2026-08-12
Human trialNCT02867267 — The Efficacy and Safety of Thymosin Alpha 1 for Sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled phase 3 trial · retrieved 2026-08-12
